| Zhang, Zhenfeng |
NCT03949231: Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 200 | RoW | PD1/PDL1 inhibitor, Administration of PD1/PDL1 inhibitor through vein or interventional technique. | Second Affiliated Hospital of Guangzhou Medical University | Liver Cancer | 01/29 | 01/38 | | |
NCT06478108: Interventional Software for Multi-immunotherapy of Solid Tumors |
|
|
| Recruiting | 2/3 | 60 | RoW | IRSW-MIM | Second Affiliated Hospital of Guangzhou Medical University, Immuno (Guangzhou) Biomedicine S&T Ltd | Lung Cancer, Liver Cancer, Solid Tumor, Adult | 12/28 | 12/33 | | |
NCT03952065: IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC) |
|
|
| Recruiting | 2/3 | 200 | RoW | PD1/PDL1/CTLA4 inhibitors | Second Affiliated Hospital of Guangzhou Medical University | Head/Neck Neoplasm | 01/29 | 01/35 | | |
NCT03755739: Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors |
|
|
| Recruiting | 2/3 | 200 | RoW | Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy, Checkpoint inhibitor (CPI) such as Keytruda plus chemotherapy | Second Affiliated Hospital of Guangzhou Medical University | Hepatocarcinoma, Lung Cancer, Melanoma, Renal Cancer, Head and Neck Cancer, Pancreas Cancer, Ovarian Cancer, Colo-rectal Cancer, Cervical Cancer, Breast Cancer | 11/33 | 11/36 | | |
NCT06483347: Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT |
|
|
| Recruiting | 2 | 90 | RoW | ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab, Local ICIs. | Second Affiliated Hospital of Guangzhou Medical University | Lung Cancer, Inoperable Disease | 12/28 | 12/33 | | |
NCT06482801: Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT |
|
|
| Recruiting | 2 | 90 | RoW | ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab, Local ICIs. | Second Affiliated Hospital of Guangzhou Medical University | Liver Cancer, Antibody | 12/30 | 12/35 | | |
NCT06492421: Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. |
|
|
| Recruiting | 2 | 90 | RoW | ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab, Other ICIs | Second Affiliated Hospital of Guangzhou Medical University | Lung Cancer, Surgery, Non-small Cell Lung Cancer | 12/28 | 12/35 | | |
NCT06492408: Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma. |
|
|
| Recruiting | 2 | 90 | RoW | ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab, Other ICIs | Second Affiliated Hospital of Guangzhou Medical University | Hepatic Cancer, Surgery | 12/28 | 12/33 | | |
NCT04803318: Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors |
|
|
| Recruiting | 2 | 100 | RoW | Combination of three inhibitors Trametinib, Everolimus and Lenvatinib, Combination of 3 signaling pathway inhibitors specific to MEK, mTOR, and angiogenesis. | Second Affiliated Hospital of Guangzhou Medical University | Solid Tumor, Adult, Hepatocellular Carcinoma | 01/29 | 01/37 | | |
NCT04770207: Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs |
|
|
| Recruiting | 2 | 100 | RoW | Injection of drug-eluting microspheres with multiple drugs into solid tumors, Checkpoint inhibitor (CPI) such as Keytruda plus chemodrug | Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma, Solid Tumor, Adult | 11/29 | 11/35 | | |
NCT06480123: Stem Cell Derived Exome for Treatment of Diabetic Foot |
|
|
| Not yet recruiting | 1/2 | 50 | RoW | Skin drug prepared with exome originated from stem cell | Second Affiliated Hospital of Guangzhou Medical University | Diabetic Foot, Stem Cell | 12/28 | 12/33 | | |
NCT05187338: Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 100 | RoW | ipilimumab +pembrolizumab +durvalumab | Second Affiliated Hospital of Guangzhou Medical University | Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer, Ovary Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer, Cervical Cancer, Esophageal Cancer, Sarcoma | 10/29 | 10/35 | | |
NCT03882840: Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I |
|
|
| Recruiting | 1/2 | 60 | RoW | ITNK cell therapy | Second Affiliated Hospital of Guangzhou Medical University, Hunan Zhaotai Yongren Medical Innovation Co. Ltd. | Anti-cancer Cell Immunotherapy, T Cell and NK Cell | 01/28 | 01/35 | | |
NCT06195384: Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | Neoantigen mRNA Vaccine | Second Affiliated Hospital of Guangzhou Medical University | Solid Tumor, Adult | 12/27 | 12/37 | | |
| Recruiting | 1 | 30 | RoW | Cell therapy for solid tumors | Second Affiliated Hospital of Guangzhou Medical University | Pancreas Cancer, Lung Cancer, Liver Cancer, Mesothelioma, CAR-T Cell Therapy, Solid Tumor, Adult | 11/30 | 12/36 | | |
NCT05410717: CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors |
|
|
| Recruiting | 1 | 200 | RoW | Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells | Second Affiliated Hospital of Guangzhou Medical University | Stage IV Ovarian Cancer, Testis Cancer, Refractory, Endometrial Cancer Recurrent, CAR NK | 06/30 | 05/36 | | |
NCT06195293: Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | Neoantigen Polypeptide Vaccine | Second Affiliated Hospital of Guangzhou Medical University | Solid Tumor, Adult | 12/29 | 12/37 | | |
NCT06477614: Anti-cancer DC Cell Vaccination to Treat Solid Tumors |
|
|
| Recruiting | 1 | 60 | RoW | DC cell Vaccine | Second Affiliated Hospital of Guangzhou Medical University | Solid Tumor, Adult, DC | 12/30 | 12/35 | | |
NCT04952272: Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors |
|
|
| Recruiting | 1 | 50 | RoW | CpG-ODN, Interventional therapy technique including microwave ablation or drug-eluting beads | Second Affiliated Hospital of Guangzhou Medical University, Guangdong Zhaotai InVivo Biomedicine Co. Ltd. | Lung Cancer, Hepatocellular Carcinoma, Solid Tumor | 06/29 | 06/36 | | |
NCT03198052: GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers |
|
|
| Recruiting | 1 | 30 | RoW | CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR, Administration of CAR-T cells through vein or interventional technique. | Second Affiliated Hospital of Guangzhou Medical University, Hunan Zhaotai Yongren Medical Innovation Co. Ltd., Guangdong Zhaotai InVivo Biomedicine Co. Ltd. | Lung Cancer, Cancer, Immunotherapy, CAR-T Cell | 08/26 | 08/36 | | |
NCT05060796: Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC |
|
|
| Recruiting | 1 | 11 | RoW | CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells | Second Affiliated Hospital of Guangzhou Medical University | Non Small Cell Lung Cancer | 11/29 | 11/34 | | |
| Recruiting | 1 | 30 | RoW | GPC3 and/or TGFβ targeting CAR-T cells | Second Affiliated Hospital of Guangzhou Medical University, Hunan Zhaotai Yongren Medical Innovation Co. Ltd., Guangdong Zhaotai InVivo Biomedicine Co. Ltd., First Affiliated Hospital, Sun Yat-Sen University | Hepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation, T Cell, Squamous Cell Lung Cancer | 08/29 | 08/36 | | |
NCT03778814: TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | TCR-T cells | Second Affiliated Hospital of Guangzhou Medical University, Tcell Immune (Guangzhou) Science and Technology Ltd. | Nonsmall Cell Lung Cancer, Solid Tumor, Adult | 12/29 | 12/36 | | |
NCT04842812: Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors |
|
|
| Recruiting | 1 | 40 | RoW | TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3 | Second Affiliated Hospital of Guangzhou Medical University, Guangdong Zhaotai InVivo Biomedicine Co. Ltd. | Liver Cancer, Lung Cancer, Breast Cancer, Colo-rectal Cancer, Brain Tumor, Solid Tumor, Adult, PD1, CTLA4 | 12/29 | 01/35 | | |
NCT05779917: Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers |
|
|
| Recruiting | 1 | 30 | RoW | CAR-T cells | Second Affiliated Hospital of Guangzhou Medical University, Fapon Biotherapy Inc. | Pancreas Cancer, CAR-T Cell Therapy, Mesothelin, Solid Tumor, Adult | 03/29 | 03/36 | | |
| Recruiting | N/A | 250 | RoW | inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group. | Second Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital of Guangzhou Medical University, Sun Yat-sen University | Lung Cancer, Gene Abnormality, Gene Product Sequence Variation, Cancer | 07/30 | 07/39 | | |
| Lian, Hui |
NCT03949231: Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma |
|
|
| Recruiting | 3 | 200 | RoW | PD1/PDL1 inhibitor, Administration of PD1/PDL1 inhibitor through vein or interventional technique. | Second Affiliated Hospital of Guangzhou Medical University | Liver Cancer | 01/29 | 01/38 | | |
NCT03952065: IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC) |
|
|
| Recruiting | 2/3 | 200 | RoW | PD1/PDL1/CTLA4 inhibitors | Second Affiliated Hospital of Guangzhou Medical University | Head/Neck Neoplasm | 01/29 | 01/35 | | |
| Xiong, Longgen |
DEFORM, NCT05848102: Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis |
|
|
| Recruiting | 4 | 166 | RoW | dapagliflozin | Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Third Affiliated Hospital, Sun Yat-Sen University, Second Affiliated Hospital of Guangzhou Medical University, Jieyang People's Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, Affiliated Hospital of Guangdong Medical University, Yuebei People's Hospital, Zhongshan People's Hospital, Guangdong, China | Functional Mitral Regurgitation | 10/24 | 04/25 | | |
| Not yet recruiting | N/A | 176 | RoW | EECP, Sham-EECP | Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Third Affiliated Hospital, Sun Yat-Sen University, Second Affiliated Hospital of Shantou University Medical College, Second Affiliated Hospital of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Jieyang People's Hospital | Mitral Regurgitation | 12/28 | 12/28 | | |
